No Data
No Data
Hong Kong stock market fluctuations | CXO concept stocks continue to rise in early trading. The Biosecurity Law is still waiting for the Senate to vote. Citigroup said that the stock price of the Chinese pharmaceutical company has been undervalued.
CXO concept stocks continued to rise in the morning session. As of the time of writing, Wuxi Bio (02269) rose 4.6% to HK$11.82; Wuxi Apptec (02359) rose 4.51% to HK$35.95; Pharmaron (03759) rose 3.84% to HK$9.73; Asymchem Laboratories (06821) rose 3.84% to HK$41.95.
Hong Kong stocks rebounded collectively with the CRO concept stocks, WuXi AppTec announced another 1 billion yuan buyback. The Biosafety Law is still awaiting a vote in the Senate.
CRO concept stocks rebounded collectively. As of the time of writing, Pharmaron (03759) rose by 4.57%, at HKD 9.38; WuXi AppTec (02359) rose by 4.04%, at HKD 33.5; Frontage Holdings (01521) rose by 3.57%, at HKD 0.58.
Contract research organizations are generally declining. Wuxi Apptec (02359) fell 9.74%. The uncertainty of the Biosecurity Law Bill weakened investor confidence.
Jinwu Finance News | The concept of contract research organizations is generally trending downward. Wuxi Apptec (02359) fell 9.74%, Frontage (01521) fell 5.36%, Tigermed (03347) fell 4.57%, Wuxi Bio (02269) fell 3.7%, and Pharmaron (03759) fell 3.13%. Citigroup has released a report stating that the U.S. House of Representatives has passed the Biosecurity Bill, but it is currently unknown whether the Senate will adopt the House version of the bill, or consider another version, or even incorporate the Biosecurity Bill into a larger comprehensive bill. Nevertheless, Citigroup believes that
HK stocks fluctuate | CRO concept stocks plummeted in early trading. The U.S. House of Representatives has passed the draft of the Biosecurity Law, and related companies have quickly issued clarification announcements.
CRO concept stocks tumbled in the morning session, as of the time of publication, wuxi apptec (02359) fell by 9.74%, closing at HK$32.45; frontage (01521) fell by 10.71%, closing at HK$0.5; pharmaron (03759) fell by 4.31%, closing at HK$8.87; tigermed (03347) fell by 3.66%, closing at HK$26.35.
With a compound annual growth rate of only 2.6% over the past five years, China's top 100 pharmaceutical companies are entering an adjustment period. How will the industry break through under internal and external pressures?
According to the data from China Meheco Group, in 2023, multiple operation indicators of the pharmaceutical industry's leading companies have declined. The compound annual growth rate of the top 100 pharmaceutical companies in the country in the past five years is only 2.6%, and the industry as a whole has entered the adjustment phase from the initial high-speed growth. Behind the weak growth, the health industry is also undergoing transformation: overseas licensing trades for innovative drugs have reached a new high, and leading companies are accelerating outward expansion...
Founder Securities: the revenue growth rate of the pharmacy sector slows down, and the concentration is expected to accelerate.
The individual account reform of medical insurance has led to a decrease in personal account income, affecting pharmaceutical sales and pharmacy business relying on individual account payments. In 2023, pharmacy medical insurance personal account expenditures decreased by 9%, and this trend is expected to continue in 2024.
No Data
No Data